About this trial
Polyendocrine Metabolic Ovarian Syndrome (PMOS) is a common endocrine and metabolic disorder associated with insulin resistance, hyperandrogenism, and an increased risk of long-term metabolic complications. Fetuin-A and resistin are adipokines implicated in insulin resistance and chronic inflammation and may serve as potential biomarkers for metabolic dysfunction in women with PMOS.
This prospective observational case-control study aims to compare serum and salivary Fetuin-A and resistin levels between women with PMOS and healthy controls. The study will evaluate the correlation between serum and salivary biomarker concentrations and investigate their associations with insulin resistance, lipid profile, and hormonal parameters. The findings may help determine whether salivary measurements can serve as reliable non-invasive biomarkers for the diagnosis and metabolic assessment of PMOS.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Female, aged 18-35 years
Diagnosis of Polyendocrine Metabolic Ovarian Syndrome (PMOS) according to the Rotterdam criteria
BMI <30 kg/m²
Written informed consent
Disqualifiers
Pregnancy or breastfeeding
Diabetes mellitus
Chronic kidney or liver disease
Thyroid dysfunction
Trial population
Women aged 18-35 years with Polyendocrine Metabolic Ovarian Syndrome (PMOS) and age-matched healthy women recruited from the outpatient gynecology and endocrinology clinics of Istinye University. Participants will undergo clinical evaluation and fasting blood and unstimulated saliva collection for biochemical analyses.
Trial design
Case-control
Prospective
Treatments tested in this trial
Blood and Saliva Biomarker Assessment
Diagnostic testParticipants will provide fasting venous blood and unstimulated saliva samples for measurement of Fetuin-A and resistin concentrations using enzyme-linked immunosorbent assay (ELISA). Metabolic and hormonal parameters, including fasting glucose, fasting insulin, HbA1c, lipid profile, total testosterone, sex hormone-binding globulin (SHBG), and dehydroepiandrosterone sulfate (DHEAS), will also be assessed. No therapeutic intervention will be administered.
Treatment groups
Trial outcomes
Primary outcomes
Correlation Between Serum and Salivary Fetuin-A and Resistin Levels
To determine the correlation between serum and salivary Fetuin-A and resistin concentrations in women with Polyendocrine Metabolic Ovarian Syndrome (PMOS) and healthy controls.
Secondary outcomes
Serum Fetuin-A Levels
Comparison of serum Fetuin-A concentrations between women with PMOS and healthy controls.
Salivary Fetuin-A Levels
Comparison of salivary Fetuin-A concentrations between women with PMOS and healthy controls
Serum Resistin Levels
Comparison of serum resistin concentrations between women with PMOS and healthy controls.
Salivary Resistin Levels
Comparison of salivary resistin concentrations between women with PMOS and healthy controls.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: